Inventor
PIERCE GLENN
US26 patents
⚠️ This page may combine multiple inventors who share the name “PIERCE GLENN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BIOVERATIV THERAPEUTICS INC
16 patentsUS9867873B2Jan 16, 2018
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC17 citations94
US9675676B2Jun 13, 2017
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC19 citations92
US9629903B2Apr 25, 2017
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC17 citations92
US9623091B2Apr 18, 2017
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC16 citations92
US11266720B2Mar 8, 2022
Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
BIOVERATIV THERAPEUTICS INC6 citations84
US10898554B1Jan 26, 2021
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC6 citations84
US10568943B2Feb 25, 2020
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC6 citations84
US10561714B2Feb 18, 2020
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC3 citations84
US10548954B2Feb 4, 2020
Factor IX polypeptides and methods of use thereof
BIOVERATIV THERAPEUTICS INC5 citations84
US10881742B2Jan 5, 2021
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
BIOVERATIV THERAPEUTICS INC5 citations83
US11286528B2Mar 29, 2022
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
BIOVERATIV THERAPEUTICS INC4 citations82
US10221455B2Mar 5, 2019
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
BIOVERATIV THERAPEUTICS INC5 citations82
US12186375B2Jan 7, 2025
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
BIOVERATIV THERAPEUTICS INC1 citations73
US11225650B2Jan 18, 2022
Methods of using FIX polypeptides
BIOVERATIV THERAPEUTICS INC5 citations72
US12371747B2Jul 29, 2025
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
BIOVERATIV THERAPEUTICS INC0 citations60
US11747351B2Sep 5, 2023
Assays to monitor bleeding disorders
BIOVERATIV THERAPEUTICS INC0 citations59